Patent application number | Description | Published |
20080289963 | Gel for Isoelectric Focusing - The present invention relates to the field of electrophoresis and more specifically to a gel or strip for separating peptide components by isoelectric focusing by producing IPG (immobilised pH gradient) gels or strips in a novel way before focusing. More closely, the peptides are focused in a novel IPG gel including an uneven or non-linear pH gradient having at least three separate stepwise arranged pH-intervals. After focusing the peptide resolution is high and the peptides are evenly distributed along the gel. | 11-27-2008 |
20090026081 | METHOD, COMPOSITION AND KIT FOR ISOELECTRIC FOCUSING - The present invention relates to a method, composition and a kit for isoelectric focusing. More closely, the present invention involves the use of to modified carrier ampholytes which are easy to separate from the proteins/peptides following finished focusing. The modification is that the carrier ampholytes are derivatised with handles interacting with a solid phase/matrix which makes them easy to remove and separate from the peptides after finished focusing. In this way, there is very little or no background from carrier ampholytes in the following MS-spectra. | 01-29-2009 |
20100143895 | METHODS AND SYSTEMS FOR ADDING A REAGENT TO AN ANALYTE IN A GEL - The present invention relates to methods and systems for adding a reagent to an analyte in a gel. The invention further provides methods and systems for transferring liquid analyte reagent mixtures from a gel to a second vessel, such as a microtitre plate. The invention is useful in the manipulation of biological molecules such as nucleic acids, carbohydrates, proteins and peptides. In particular, the invention has utility for manipulating proteins and peptides in isoelectric focusing gels. | 06-10-2010 |
20100163416 | ELECTRODIC BRIDGE - The present invention relates to an electrode bridge or sample application bridge for use in electrophoresis, preferably isoelectric focusing, IEF. More closely, the invention relates to an electrodic bridge or sample loading bridge for preventing denaturant depletion from the IPG (immobilised pH gradient) gel and, optionally, for loading samples onto the IPG gel. The pH of the bridge is adjustable for adoption to positioning at the acid as well as basic end of the IPG strips. | 07-01-2010 |
Patent application number | Description | Published |
20080233660 | Solid phase labeling method - The invention provides for the labeling of antibodies with a fluorescent label, using a solid support comprising an affinity for an Fc portion of an antibody. Thus, the invention provides a method for labeling an antibody or fragment thereof with a fluorescent label, comprising the steps of immobilizing an antibody on the solid support and covalently coupling a fluorescent label to the immobilized antibody, as well as a kit for performing such method. | 09-25-2008 |
20090220975 | USE OF PROTEIN SATB2 AS A MARKER FOR COLORECTAL CANCER - The invention provides new methods, means and uses in connection with detection, characterization and prognosis of colo-rectal cancer, via the identification of the SATB2 protein as a marker for this cancer type. | 09-03-2009 |
20110003854 | BREAST CANCER TREATMENT AND TREATMENT PREDICTION - The present invention provides a new method and means for determining whether a mammalian subject having a breast cancer is likely to benefit from an endocrine treatment. The method comprise the steps of: providing a sample earlier obtained from said subject; evaluating the amount of CRABP2 protein present in at least part of said sample, and determining a sample value corresponding to said amount; comparing the obtained sample value with a reference value; and, if said sample value is higher than said reference value, concluding that the subject is likely to benefit from an endocrine treatment. | 01-06-2011 |
20110021635 | RBM3 AS A MARKER FOR BREAST CANCER PROGNOSIS - The present invention provides means, such as a method, for determining whether a prognosis for a mammalian subject having a breast cancer is better than a reference prognosis. The method comprises the steps of: providing a sample earlier obtained from the subject; evaluating the amount of RBM3 protein present in at least part of said sample, and determining a sample value corresponding to said evaluated amount; comparing the sample value obtained with a reference value associated with said reference prognosis; and, if said sample value is higher than said reference value, concluding that the prognosis for said subject is better than said reference prognosis. | 01-27-2011 |
20110158988 | ANTIBODIES AGAINST EXTRACELLULAR DOMAINS 2 AND 3 OR HER2 - The present invention relates to an affinity ligand capable of selective interaction with a subset consisting of 37 consecutive amino acid residues or less from extracellular domains 2 and 3 of HER2, wherein the subset comprises the amino acid sequence LQVF and/or ESFDGD1 and to polypeptides consisting of such subsets. | 06-30-2011 |
20120034218 | RBM3 in Colorectal Cancer Prognostics - The present invention provides means, such as a method, for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA molecule in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and | 02-09-2012 |
20120269764 | RBM3 as a Marker for Malignant Melanoma Prognosis - A method for determining whether a mammalian subject having a malignant melanoma belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group is provided. The method comprises the steps of: evaluating an amount of RBM3 protein in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group. | 10-25-2012 |
20140072991 | QUANTITATIVE STANDARD FOR MASS SPECTROMETRY OF PROTEINS - The present invention provides a method of determining the absolute amount of a target polypeptide in a sample, said method comprising the following steps: (a) adding (aa) a fusion polypeptide to said sample, said fusion polypeptide comprising (i) at least one tag sequence and (ii) a subsequence of the target polypeptide; and (ab) a known absolute amount of a tag polypeptide comprising or consisting of said tag sequence according to (aa) to said sample, wherein said fusion polypeptide on the one hand is mass-altered as compared to said target polypeptide and said tag polypeptide on the other hand, for example, said fusion polypeptide on the one hand and said target polypeptide and said tag polypeptide on the other hand are differently isotope labeled; (b) performing proteolytic digestion of the mixture obtained in step (a); (c) subjecting the result of proteolytic digestion of step (b), optionally after chromatography, to mass spectrometric analysis; and (d) determining the absolute amount of said target polypeptide from (i) the peak intensities in the mass spectrum acquired in step (c) of said fusion polypeptide, said tag polypeptide and said target polypeptide and (ii) said known absolute amount of said tag polypeptide. | 03-13-2014 |
20140221507 | Biomarker of Renal Impairment - There is provided a method of determining whether a subject belongs to a first or a second group of subjects, wherein the risk of having or developing of a renal impairment is higher in the first group than in the second group, comprising the steps of: a) measuring an amount of fibulin 1 in a sample from the subject to obtain a sample value; b) comparing the sample value to a reference value; and if the sample value is higher than the reference value, c1) concluding that the subject belongs to the first group; and if the sample value is lower than the reference value, c2) concluding that the subject belongs to the second group, wherein the sample is an optionally modified sample derived from urine or blood, such as an optionally diluted serum or plasma sample. Associated means are also provided. | 08-07-2014 |
20140295462 | RBM3 Protein in Colorectal Cancer Prognostics - The present invention provides means, such as a method, for determining whether a mammalian subject having a colorectal cancer belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group. The method comprises the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA molecule in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and | 10-02-2014 |